High-Intensity Focused Ultrasound Treatment for Advanced Pancreatic Cancer

Table 2

Statistics of the number of sessions, pain relief, clinical benefit rate, and survival of advanced pancreatic cancer patients undergoing HIFU therapy or in conjunction with chemotherapy or radiotherapy.

	Session	Pain relief	Complete relief (CR)	Partial relief (PR)	Clinical beneficial rate (CBR)	Survival (months)
HIFU	6.7; (𝑛=653)	71.33%; (𝑛=1938)	29.66%; (𝑛=1534)	39.83%; (𝑛=1534)	71.06%; (𝑛=508)	10.03; (𝑛=806)
HIFU + chemo	7.4; (𝑛=471)	59.72%; (𝑛=602)	8.35%; (𝑛=395)	45.39%; (𝑛=395)	74.76%; (𝑛=353)	10.16; (𝑛=270)
Chemotherapy		31.5%; (𝑛=261)	4.31%; (𝑛=100)	23.22%; (𝑛=100)	38.85%; (𝑛=222)	7.40; (𝑛=112)
HIFU + radio	5.2; (𝑛=130)	65.91%; (𝑛=176)	27.84%; (𝑛=176)	38.07%; (𝑛=176)	82.15%; (𝑛=89)	15.55; (𝑛=101)
Radiotherapy		29.65%; (𝑛=67)	3.76%; (𝑛=67)	25.89%; (𝑛=67)	60.36%; (𝑛=95)